Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether the administration of tanezumab,
an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients
receiving background non-NSAID therapy.